Similar articles

• The Legacy of Intraperitoneal Therapy in Ovarian Cancer: Why Are We Never Satisfied With the Answer.

  Edwards RP. Edwards RP. Oncology (Williston Park). 2015 Sep;29(9):705-6. Oncology (Williston Park). 2015. PMID: 26384809 No abstract available.
• Re: "cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase II trial." - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study.

  Ansaloni L, De Iaco P, Frigerio L. Ansaloni L, et al. Gynecol Oncol. 2012 Apr;125(1):279-81. doi: 10.1016/j.ygyno.2012.01.001. Epub 2012 Jan 9. Gynecol Oncol. 2012. PMID: 22233688 No abstract available.
• Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer.

  Oseledchyk A, Zivanovic O. Oseledchyk A, et al. Oncology (Williston Park). 2015 Sep;29(9):695-701. Oncology (Williston Park). 2015. PMID: 26384807 Review.
• The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.

  Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. Spiliotis J, et al. J BUON. 2011 Jan-Mar;16(1):74-9. J BUON. 2011. PMID: 21674853
• [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

  Ferron G, Martinez A, Mery E, Querleu D, Thomas F, Chatelut E, Gladieff L. Ferron G, et al. Bull Cancer. 2009 Dec;96(12):1243-52. doi: 10.1684/bdc.2009.1005. Bull Cancer. 2009. PMID: 19948452 Review. French.